荣昌生物
(688331)
| 流通市值：105.77亿 | | | 总市值：367.47亿 |
| 流通股本：1.62亿 | | | 总股本：5.64亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 721,718,278.96 | 762,492,395.54 | 664,964,952 | 676,124,693.28 |
| 应收票据及应收账款 | 535,574,498.81 | 587,688,671.37 | 482,106,303.7 | 437,571,784.17 |
| 其中：应收票据 | 203,611,667.29 | 204,299,928.35 | 147,677,318.74 | 129,647,429.43 |
| 应收账款 | 331,962,831.52 | 383,388,743.02 | 334,428,984.96 | 307,924,354.74 |
| 应收款项融资 | 10,876,421.81 | 11,097,822.85 | 51,264,381.26 | 103,052,899.78 |
| 预付款项 | 211,678,254.07 | 241,373,752 | 287,105,369.05 | 300,231,183.16 |
| 其他应收款合计 | 38,016,784.67 | 24,283,132.94 | 29,200,438.94 | 30,732,282.72 |
| 存货 | 638,250,683.99 | 659,368,730.71 | 745,387,541.34 | 740,650,308.64 |
| 其他流动资产 | 4,672,775.16 | 3,491,867.9 | 3,798,780.51 | 5,278,443.85 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,160,787,697.47 | 2,289,796,373.31 | 2,524,007,322.36 | 2,493,879,928.93 |
| 非流动资产: | | | | |
| 长期股权投资 | 8,724,070.05 | 8,850,723.9 | 8,850,545.83 | 8,850,355.36 |
| 其他权益工具投资 | 71,451,198.74 | 59,313,437.97 | 53,840,867.96 | 63,482,114.8 |
| 其他非流动金融资产 | 5,037,475.88 | 4,037,475.88 | 3,038,731.56 | 2,856,774.32 |
| 固定资产 | 2,415,481,681.93 | 2,457,180,322.07 | 2,412,993,585.31 | 2,402,126,744.68 |
| 在建工程 | 274,386,452.19 | 283,231,455.78 | 309,112,443.03 | 376,667,551.29 |
| 使用权资产 | 77,016,451.12 | 93,753,714.63 | 108,139,896.18 | 124,816,666.64 |
| 无形资产 | 144,283,335.84 | 143,131,261.71 | 142,680,567.46 | 144,062,633.49 |
| 长期待摊费用 | 3,436,262.42 | 4,324,896.83 | 5,493,772.56 | 6,478,814.32 |
| 其他非流动资产 | 146,740,422.38 | 154,898,506.74 | 144,555,680.75 | 131,317,462.94 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 3,146,557,350.55 | 3,208,721,795.51 | 3,188,706,090.64 | 3,260,659,117.84 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,307,345,048.02 | 5,498,518,168.82 | 5,712,713,413 | 5,754,539,046.77 |
| 流动负债: | | | | |
| 短期借款 | 1,131,441,051.38 | 1,083,853,548.13 | 1,026,766,746.38 | 930,162,423.13 |
| 应付票据及应付账款 | 183,333,479.65 | 162,250,106.68 | 184,834,362.99 | 133,158,441.74 |
| 应付账款 | 183,333,479.65 | 162,250,106.68 | 184,834,362.99 | 133,158,441.74 |
| 合同负债 | 3,464,453.46 | 3,143,688.86 | 3,220,361.43 | 3,911,974.33 |
| 应付职工薪酬 | 202,014,930.29 | 209,986,022.76 | 199,275,853.26 | 192,534,656.39 |
| 应交税费 | 36,662,017.3 | 37,058,544.84 | 40,837,332.71 | 12,945,103.5 |
| 其他应付款合计 | 276,552,827.94 | 314,995,392.79 | 272,540,452.82 | 288,194,056.63 |
| 一年内到期的非流动负债 | 500,378,057.66 | 348,684,938.4 | 118,158,847.27 | 65,717,044.34 |
| 其他流动负债 | 11,108,272.72 | 18,324,410.71 | 15,154,007.15 | 12,097,042.02 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 2,344,955,090.4 | 2,178,296,653.17 | 1,860,787,964.01 | 1,638,720,742.08 |
| 非流动负债: | | | | |
| 长期借款 | 1,063,318,088.45 | 1,195,878,046.86 | 1,341,279,937.63 | 1,341,637,543.48 |
| 租赁负债 | 33,902,632.34 | 42,093,510.05 | 46,536,564.21 | 60,575,398.53 |
| 递延收益 | 93,744,141.76 | 96,049,337.8 | 95,428,408.34 | 48,995,823.89 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 1,190,964,862.55 | 1,334,020,894.71 | 1,483,244,910.18 | 1,451,208,765.9 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 3,535,919,952.95 | 3,512,317,547.88 | 3,344,032,874.19 | 3,089,929,507.98 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 544,332,083 | 544,332,083 | 544,332,083 | 544,332,083 |
| 资本公积 | 6,281,946,295.16 | 6,290,989,900.9 | 6,287,590,554.06 | 6,269,443,456.91 |
| 减:库存股 | 408,910,121.8 | 445,329,702.16 | 444,896,381.34 | 438,160,075.98 |
| 其他综合收益 | -69,927,500.66 | -81,920,470.23 | -93,408,689.99 | -77,035,769.43 |
| 未分配利润 | -4,576,015,660.63 | -4,321,871,190.57 | -3,924,937,026.92 | -3,633,970,155.71 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,771,425,095.07 | 1,986,200,620.94 | 2,368,680,538.81 | 2,664,609,538.79 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,771,425,095.07 | 1,986,200,620.94 | 2,368,680,538.81 | 2,664,609,538.79 |
| 负债和股东权益合计 | 5,307,345,048.02 | 5,498,518,168.82 | 5,712,713,413 | 5,754,539,046.77 |
| 公告日期 | 2025-04-29 | 2025-03-28 | 2024-10-30 | 2024-08-17 |
| 审计意见(境内) | | 标准无保留意见 | | |